TL;DR
A meta-analysis published in The Lancet Psychiatry compared 21 antidepressants across 115 studies involving people with major depressive disorder followed for more than 12 weeks. Escitalopram, duloxetine and agomelatine were more likely than fluoxetine to be associated with sustained symptom improvement, while most drugs had broadly comparable results.
A meta-analysis of 21 antidepressants found that escitalopram, duloxetine and agomelatine were more likely than fluoxetine to be associated with sustained improvement in depression symptoms in studies lasting more than 12 weeks. Published Tuesday in The Lancet Psychiatry, the analysis drew on 115 studies and also compared whether participants stayed on their assigned treatment, offering evidence about outcomes beyond the roughly eight-week span of many clinical trials.
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The researchers examined studies of people with major depressive disorder who were followed for longer than 12 weeks. One study tracked participants for as long as two years. The analysis included both published and unpublished studies, according to the report. The researchers used fluoxetine, commonly known by the brand name Prozac, as the comparison drug because it is widely recognized and commonly prescribed.
The analysis measured whether participants had a “sustained response”: an improvement in symptoms that lasted until the end of a trial. It also examined whether participants discontinued treatment for any reason. The researchers treated discontinuation as an indication that symptoms may not have improved, though stopping a medication can have other reasons and the measure does not by itself establish why a participant stopped.
Most of the drugs were comparable overall for symptom improvement or how long participants remained on treatment, the report said. Escitalopram, sold as Lexapro; duloxetine, sold as Cymbalta; and agomelatine, sold as Thymanax, had a greater likelihood than fluoxetine of being linked to sustained symptom improvement. Bupropion, known by brand names including Wellbutrin and Zyban, and reboxetine, sold as Edronax, performed worse than multiple other antidepressants on measures in the analysis. The supplied report does not provide effect sizes or detailed rankings.
Evidence Beyond Short Trials
The findings address a gap between the duration of many antidepressant trials and the length of time some patients take medication. Trials commonly run for about eight weeks, while the analysis included follow-up beyond 12 weeks and, in one study, up to two years. That makes sustained response and treatment continuation relevant outcomes for patients and clinicians weighing longer-term care.
The results may help inform discussions about medication options, but they do not establish that one drug will work best for a particular person. The reported differences were described as subtle, and most medications were broadly similar on the measures considered. Individual outcomes and treatment decisions require clinical judgment; this analysis is a comparison of group results, not a prescription for any one patient.
Products Worth Considering

LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 sq ft

Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale

Therabody Theragun Mini 3rd Generation Portable Massage Gun, Black
As an affiliate, we earn on qualifying purchases.
Why Researchers Used Fluoxetine
Comparative evidence on antidepressants over longer periods has been limited, according to the report, even though depression is common and some people take medication for years. The study sought to extend comparisons past the duration of a typical clinical trial by combining evidence from 115 studies, including research that had not been published.
Fluoxetine served as the shared reference point for the comparisons. Using a familiar, commonly prescribed medication allowed the researchers to describe how other drugs performed relative to it. The findings concern major depressive disorder and the particular outcomes and follow-up periods included in the studies; they should not be read as a direct comparison of every treatment approach or as proof of long-term effects beyond the available follow-up.
“The researchers compared each drug with fluoxetine because it is a well-known medication that has been commonly prescribed.”
— The study authors, as described in The New York Times report
Limits of the Available Comparisons
The supplied report does not give effect sizes, confidence intervals or detailed drug-by-drug rankings, so readers cannot determine from it how large the differences were or how precise the estimates may be. It also does not specify how many participants were included, how results varied across individual studies, or whether findings differed among patient groups.
The analysis treated stopping a medication for any reason as indicating that symptoms had not improved. That approach may not capture why a participant discontinued, and the report does not provide a breakdown of reasons. The findings also do not establish which antidepressant is most suitable for an individual or how outcomes compare beyond the follow-up periods covered by the studies.
How Clinicians May Use the Findings
The study adds comparative evidence for longer-term outcomes, but the next step for readers and clinicians is to consider the full published analysis, including its methods, estimates and limitations. The report does not announce a change to treatment guidance or identify a new clinical recommendation. Medication choices remain individual and should be discussed with a qualified health professional, particularly before starting, stopping or changing an antidepressant.
Further research with longer follow-up and clear reporting of treatment discontinuation reasons could help clarify how durable the differences are and whether they apply consistently across patient groups. For now, the reported finding is that several drugs showed an advantage over fluoxetine for sustained response in the pooled analysis, while most comparisons were broadly similar.
Key Questions
Which antidepressants were more likely than fluoxetine to show sustained improvement?
The report says escitalopram, duloxetine and agomelatine were more likely than fluoxetine to be associated with symptom improvement that lasted through the end of the study trials.
How many studies and medications did the analysis include?
The meta-analysis compared 21 antidepressants across 115 studies of people with major depressive disorder.
What did the researchers mean by a sustained response?
They defined it as an improvement in symptoms that lasted until the trial ended. The studies followed participants for more than 12 weeks, with one study lasting as long as two years.
Does the analysis show which antidepressant will work best for an individual?
No. It reports average comparisons across studies, and most medications were broadly comparable on the outcomes described. The results do not determine the best choice for a particular person; treatment decisions should be discussed with a qualified health professional.
Source: nytimes.com
